UroGen Pharma price target raised to $54 from $23 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on UroGen Pharma to $54 from $23 and keeps a Buy rating on the shares post last week’s UGN-102 results. The new target reflects increased expectations with respect to UGN-102, particularly in terms of pricing and an increase in the probability of approval to 80% from 70%, the analyst tells investors in a research note.